10-Q quarterly report · filed Nov 4, 2026

Medline Inc (MDLN) Q3 2026 10-Q Quarterly Report

Short answer

Medline Inc (MDLN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $7.9B with net income of $194M.

Q3 2026 key financials · XBRL

Revenue
$7.9B
+2.2% QoQ
Net income
$194M
+198.5% QoQ
Operating margin
6.4%
Gross margin
24.5%
EPS (diluted)
$0.22
+214.3% QoQ

Source: XBRL data from the Medline Inc (MDLN) Q3 2026 10-Q on SEC EDGAR. USD.

Medline Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $7,856M, up 10.4% YoY from $7,115M, driven by organic volume growth
  • Gross margin 24.5% vs 26.4% YoY; net income margin 4.0% vs 4.5%; Adjusted EBITDA margin 12.2% vs 12.1%
  • Best segment: Medline Brand revenue $3,637M, up 6.6%, EBITDA margin 25.9% vs 24.1%; worst: Supply Chain Solutions margin 4.4% vs 5.5%
  • Cash and equivalents $2,321M, short-term investments $1,287M; nine-month operating cash flow $2,152M vs $1,515M
  • Headwinds: tariffs, FDA bed recall costs $60M to $210M, restructuring costs $20M to $30M; 2026 capital expenditures up to $600M

Risk Factors

  • No material changes to risk factors disclosed in the 2025 Form 10-K
  • Carried-forward risks remain unchanged for the quarter

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.